Licence holders' shortage notices, published by BfArM and read for contract manufacturers (a guess to confirm).
Burg Pharma's notice for Elektrolyt-Infusionslösung 153 mit Glucose 5 reports that Serumwerk Bernburg AG has terminated contract manufacture. The notice was last updated on 14 October 2026. It gives 1 November 2026 as the start of the shortage and 30 September 2027 as the expected end. It does not say whether Burg is looking for another manufacturer.
Burg Pharma reports that Serumwerk Bernburg AG has terminated contract manufacture and no longer produces electrolyte solutions or parenterals under contract.
BfArM's wording: Kündigung der Lohnherstellung durch Serumwerk Bernburg AG, keine Produktion von Elektrolytlösungen / Parenteralia im LohnauftragThe file downloaded on 12 November 2026 holds 531 notices on 252 active substances. In 27 of them the licence holder reports that a manufacturer has stopped or changed, or that production is moving. The notices do not say whether a new manufacturing contract is open. Of the 27:
| Medicine | Licence holder | Dates | What the notice says |
|---|---|---|---|
| Elektrolyt-Infusionslösung 153 mit Glucose 5Infusion solution | Burg Pharma GmbH | Short from 1 November 2026Expected until 30 September 2027Notice last updated 14 October 2026 | No replacement statedBurg Pharma reports that Serumwerk Bernburg AG has terminated contract manufacture and no longer produces electrolyte solutions or parenterals under contract.BfArM's wording, notice LE2026003784Kündigung der Lohnherstellung durch Serumwerk Bernburg AG, keine Produktion von Elektrolytlösungen / Parenteralia im Lohnauftrag |
| Bendacitabin 38 mg/ml (gemcitabine)Powder for solution for infusion | BENDALIS GmbH | Short from 4 December 2023Expected until 31 January 2027Notice last updated 1 December 2023 | No replacement statedThe current contract manufacturer has stopped making the finished medicine.BfArM's wording, notice LE2023004822Der derzeitige Lohnhersteller hat die Produktion des Fertigarzneimittels eingestellt. |
| Antidotum Thallii-HeylHard capsules | Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG | Short from 24 February 2021Expected until 31 December 2026Notice last updated 5 January 2026 | No manufacturer has taken it onThe former contract manufacturer, Haupt Pharma Berlin GmbH, closed its plant, so the products have to move to a new contract manufacturer. So far every available manufacturer has excluded Antidotum Thallii from the transfer for economic reasons.BfArM's wording, notice LE2026000035Durch die Betriebsschließung des bisherigen Lohnherstellers Haupt Pharma Berlin GmbH müssen die Produkte zu einem neuen Lohnhersteller transferiert werden. Dabei wurde Antidotum Thallii vom Produkttransfer aus wirtschaftlichen Gründen von bisher allen, verfügbaren Herstellern ausgeschlossenn. |
| Doxorubicin 2 mg/mlSolution for injection | BENDALIS GmbH | Short from 15 November 2024Expected until 31 December 2026Notice last updated 7 January 2026 | Additional manufacturer being addedProduction problems at the existing contract manufacturer continue. Transfer to a new, additional contract manufacturer has been initiated. The regulatory change notification will follow once production and analytical validation data are available.BfArM's wording, notice LE2026000056Die Produktionsprobleme beim bisherigen Lohnhersteller des Arzneimittels bestehen weiterhin.Der Produkttransfer zu einem neuen zusätzlichen Lohnhersteller ist initiiert. Nach Vorliegen der Validierungsdaten aus der Produktion und Analytik erfolgt die entsprechende Änderungsanzeige. |
| Erythromycin 1 g for infusionPowder for solution for infusion | Inresa Arzneimittel GmbH | Short from 9 January 2026Expected until 31 December 2026Notice last updated 7 October 2026 | Transfer under wayThe product is being transferred to another finished-product manufacturer; the site that releases batches stays the same. The transfer is not yet complete.BfArM's wording, notice LE2026003655Transfer zu einem anderen Fertigprodukthersteller (kein Endfreigeber). Transfer noch nicht abgeschlossen. |
| Tranexamic acid 100 mg/mlSolution for injection | Eugia Pharma (Malta) Limited | Short from 29 September 2025Expected until 30 March 2027Notice last updated 24 February 2026 | Moving to another production unitThe product must be transferred to another production unit. Depending on the transfer and available capacity, stock is expected no earlier than the first quarter of 2027.BfArM's wording, notice LE2026000716Das Produkt muss auf eine andere Unit transferiert werden. Je nach Tansfer/Kapazitäten bekommen wir Ware frühestes in Q1/2027. |
| NIPRUSS (sodium nitroprusside)Lyophilisate for solution for infusion | ALTAMEDICS GmbH | Short from 1 August 2026Expected until 31 December 2026Notice last updated 19 October 2026 | New source ready, awaiting approvalThe currently approved manufacturers of the active substance and of the finished medicine have stopped production. Product from the new manufacturing source is ready and can be placed on the market as soon as the regulatory procedures are approved.BfArM's wording, notice LE2026003840Die derzeit genehmigten Hersteller von Wirkstoff und Fertigarzneimittel haben die Herstellung eingestellt. Produkte aus der neuen Herstellung liegen bereit und können sofort auf den Markt gebracht werden, sobald die regulatorischen Verfahren genehmigt werden. |
These examples summarise licence holders' notices published by BfArM; the holders are responsible for what they report. The notices describe manufacturing circumstances. They do not identify open procurement processes.
Several licence holders report shortages of the same active substance in the same family of dosage forms. The bars count the licence holders in the downloaded file. They do not measure manufacturing capacity or show whether the holders use different manufacturers. 46 active substances were reported by two or more holders.
Bar length is the number of licence holders, on one scale up to 9. The dates run from the earliest reported start to the latest expected end among the included notices. Relevant for hospitals means at least one included notice is marked so.
BfArM's full list, read every day, with the EU list and other national lists next (a guess to confirm).
By active substance and dosage form, so oral solids, injections and the rest are counted apart.
A manufacturer stopping or changing, a transfer under way, several licence holders short at once.
A monthly list and alerts for the dosage forms you make (a guess to confirm), with the notice behind every line.
The founders' names and backgrounds go here, with the company behind the product and links to related work in supply chains and life-science markets.
From the shortage notices that licence holders submit and BfArM, Germany's Federal Institute for Drugs and Medical Devices, publishes on PharmNet.Bund. The published list can be downloaded as a CSV file for automated use. This draft uses the file downloaded on 12 November 2026.
The notices are public. This draft groups them by substance and dosage form, translates their reasons and separates manufacturers that have stopped from transfers already under way. Whether a licence holder is looking for another manufacturer still has to be established.
Germany today. Other EU national lists and the EMA list are planned. (a guess to confirm)
Yes. The list is filtered to your forms, for example injections or oral solids. (a guess to confirm)
Ask for this month's list for your dosage forms. (a guess to confirm)